scholarly journals PACE Continuous Innovation Indicators—a novel tool to measure progress in cancer treatments

2015 ◽  
Vol 9 ◽  
Author(s):  
Silvia Paddock
Keyword(s):  
Cancer Treatments ◽  
Continuous Innovation ◽  
Innovation Indicators

scholarly journals Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)

2017 ◽  
Vol 6 ◽  
pp. 1-12 ◽  
Author(s):  
Neon Brooks ◽  
Mario Campone ◽  
Silvia Paddock ◽  
Scott Shortenhaus ◽  
David Grainger ◽  
...  
Keyword(s):  
Overall Survival ◽  
Historical Data ◽  
Cancer Treatments ◽  
Continuous Innovation ◽  
Innovation Indicators

1211 Continuous Innovation Indicators™ - a flexible tool to evaluate progress in cancer treatments

2015 ◽  
Vol 51 ◽  
pp. S175
Author(s):  
S. Paddock ◽  
L. Brum ◽  
K. Sorrow ◽  
S. Thomas ◽  
S. Spence ◽  
...  
Keyword(s):  
Cancer Treatments ◽  
Flexible Tool ◽  
Continuous Innovation ◽  
Innovation Indicators

The PACE continuous innovation Indicators: A flexible tool to evaluate progress in cancer treatments.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e17783-e17783 ◽  
Author(s):  
Silvia Paddock ◽  
Lauren Brum ◽  
Kathleen Sorrow ◽  
Samuel Thomas ◽  
Susan Spence ◽  
...  
Keyword(s):  
Cancer Treatments ◽  
Flexible Tool ◽  
Continuous Innovation ◽  
Innovation Indicators

scholarly journals Pace Continuous Innovation Indicators—A Novel Tool To Measure Progress In Cancer Treatments

2015 ◽  
Vol 18 (3) ◽  
pp. A35
Author(s):  
S. Paddock ◽  
L.M. Brum ◽  
K. Sorrow ◽  
S. Thomas ◽  
S. Spence ◽  
...  
Keyword(s):  
Cancer Treatments ◽  
Continuous Innovation

scholarly journals Pace Continuous Innovation Indicators Data Support Dynamic Value Assessments Of Pharmaceuticals

2016 ◽  
Vol 19 (3) ◽  
pp. A107
Author(s):  
S Thomas ◽  
C Goodman ◽  
S Paddock ◽  
SH Shortenhaus ◽  
J Ferguson ◽  
...  
Keyword(s):  
Continuous Innovation ◽  
Data Support ◽  
Innovation Indicators

scholarly journals Dynamic value assessments in oncology supported by the PACE Continuous Innovation Indicators

2017 ◽  
Vol 13 (25) ◽  
pp. 2253-2264 ◽  
Author(s):  
Silvia Paddock ◽  
Clifford Goodman ◽  
Scott Shortenhaus ◽  
David Grainger ◽  
Jacqueline Zummo ◽  
...  
Keyword(s):  
Continuous Innovation ◽  
Innovation Indicators

scholarly journals Assessing the impact of clinical trial designs on progress against cancer using the PACE Continuous Innovation Indicators™

2016 ◽  
Vol 27 ◽  
pp. vi351
Author(s):  
S. Paddock ◽  
S. Thomas ◽  
A. Kanli ◽  
J. Zummo ◽  
D. Grainger ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Continuous Innovation ◽  
Clinical Trial Designs ◽  
Innovation Indicators ◽  
The Impact

A Case Study on the Un-Used Capacity Assessment Using Time Driven Activity Based Costing for Magnetic Components

2020 ◽  
Vol 6 (1) ◽  
pp. 18-39
Author(s):  
Areena Zaini ◽  
Haryantie Kamil ◽  
Mohd Yazid Abu
Keyword(s):  
Historical Data ◽  
Manufacturing Sector ◽  
Type I ◽  
Activity Based Costing ◽  
Cost Rate ◽  
Continuous Innovation ◽  
Magnetic Components ◽  
Alignment Process ◽  
Capacity Cost

The Electrical & Electronic (E&E) company is one of Malaysia’s leading industries that has 24.5% in manufacturing sector production. With a continuous innovation of E&E company, the current costing being used is hardly to access the complete activities with variations required for each workstation to measure the un-used capacity in term of resources and cost. The objective of this work is to develop a new costing structure using time-driven activity-based costing (TDABC) at . This data collection was obtained at E&E company located at Kuantan, Pahang that focusing on magnetic component. The historical data was considered in 2018. TDABC is used to measure the un-used capacity by constructing the time equation and capacity cost rate. This work found three conditions of un-used capacity. Type I is pessimistic situation whereby according to winding toroid core, the un-used capacity of time and cost are -14820 hours and -MYR2.60 respectively. It means the system must sacrifice the time and cost more than actual apportionment. Type II is most likely situation whereby according to assembly process, the un-used capacity of time and cost are 7400 hours and MYR201575.45 respectively. It means the system minimize the time and cost which close to fully utilize from the actual apportionment. Type III is optimistic situation whereby according to alignment process, the un-used capacity of time and cost are 4120 hours and MYR289217.15 respectively. It means the system used small amount of cost and time from the actual apportionment.

Immunotherapy in cancer: mechanisms of immune response and their place in cancer treatments

2017 ◽  
Vol 1 (38) ◽  
Author(s):  
Dana Lucia Stănculeanu ◽  
Carmen Ardeleanu ◽  
Daniela Zob ◽  
Raluca Ioana Mihăilă ◽  
Oana Cătălina Toma ◽  
...  
Keyword(s):  
Immune Response ◽  
Cancer Treatments
Sign in / Sign up

Export Citation Format

Share Document